Prevention and treatment of tuberculosis infection in candidates for biologic therapy: A multidisciplinary consensus statement adapted to the dermatology patient.

Authors :: Rodríguez-Jiménez P
Mir-Viladrich I
Chicharro P
Solano-López G
López-Longo FJ
Taxonera C
Sánchez-Martínez P
Martínez-Lacasa X
García-Gasalla M
Dorca J
Arias-Guillén M
García-García JM
Dauden E
Source :: Actas dermo-sifiliograficas [Actas Dermosifiliogr (Engl Ed)] 2018 Sep; Vol. 109 (7), pp. 584-601. Date of Electronic Publication: 2018 Jun 02.
Publication Year :: 2018
Abstract: Patients with chronic inflammatory diseases being treated with immunosuppressive drugs, and with tumor necrosis factor inhibitors in particular, have an increased risk of infection by Mycobacterium tuberculosis. Screening for latent tuberculosis infection and preventive therapy to reduce the risk of progression to active tuberculosis are mandatory in this group of patients. This updated multidisciplinary consensus document presents the latest expert opinions on the treatment and prevention of tuberculosis in candidates for biologic therapy and establishes recommendations based on current knowledge relating to the use of biologic agents.<br /> (Copyright © 2018 AEDV. Publicado por Elsevier España, S.L.U. All rights reserved.)

Subjects :: Antibodies, Monoclonal adverse effects
Antibodies, Monoclonal therapeutic use
Antitubercular Agents administration & dosage
Drug Monitoring
Hidradenitis Suppurativa drug therapy
Humans
Immunity, Cellular
Latent Tuberculosis diagnosis
Patient Selection
Psoriasis drug therapy
Risk
T-Lymphocyte Subsets immunology
Tuberculosis drug therapy
Tumor Necrosis Factor-alpha antagonists & inhibitors
Antitubercular Agents therapeutic use
Biological Therapy adverse effects
Latent Tuberculosis drug therapy
Tuberculosis prevention & control

Full Text Access

Tools